Known targets — ChEMBL curated mechanism
ACVR1ADORA1ADORA2AADORA2BADORA3ESR1ESR2FLT3GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSC1HRH1HTR7IDH1IDH2IRAK1JAK1JAK2JAK3MEN1OPRM1P2RX3PDE5ASCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASIGMAR1SLC6A2SYKTACR1TOP2ATYK2
The experimentally established mechanism targets of Citric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 known ✓ | O00255 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.79 |
| ▸ | HMGCR | P04035 | 1/20 | 0.48 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.48 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.48 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 3/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | SLC13A5 | Q86YT5 | 4/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ACLY | P53396 | 3/20 | 0.39 |
| ▸ | CPT2 | P23786 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Citric Acid SCHEMBL5874339 | 1.00 | ALDH1A1 (0.79) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL7791059 | 0.97 | ALDH1A1 (0.75) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL28291026 | 0.90 | ALDH1A1 (0.71) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL30359537 | 0.89 | ALDH1A1 (0.88) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL2396390 | 0.89 | ALDH1A1 (0.88) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL3417188 | 0.89 | ALDH1A1 (1.00) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL10896997 | 0.89 | ALDH1A1 (1.00) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL240402 | 0.89 | ALDH1A1 (1.00) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL842 | 0.89 | ALDH1A1 (1.00) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL725546 | 0.89 | ALDH1A1 (1.00) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017046709-A1 | BIOCIDES AND PREPARATION THEREOF | BIOLOGICAL CHEMICAL TECHNOLOGIES (PTY) LTD T/A BIODX (ZA) | 2017-03-23 | — | — | WO | claimed |
| EP-3036299-A1 | LAPPING SLURRY HAVING A CATIONIC SURFACTANT | Diamond Innovations, Inc. (US) | 2016-06-29 | — | — | EP | claimed |
| WO-2015026477-A1 | LAPPING SLURRY HAVING A CATIONIC SURFACTANT | DIAMOND INNOVATIONS, INC. (US) | 2015-02-26 | — | — | WO | claimed |
| CN-102149846-B | Methods and solutions for preventing the formation of metal particulate defect matter upon a substrate after a plating process | LAM RESERCH CORP | 2014-04-02 | — | — | CN | claimed |
| CN-102149846-A | Methods and solutions for preventing the formation of metal particulate defect matter upon a substrate after a plating process | LAM RES | 2011-08-10 | — | — | CN | claimed |
| WO-2010027950-A2 | METHODS AND SOLUTIONS FOR PREVENTING THE FORMATION OF METAL PARTICULATE DEFECT MATTER UPON A SUBSTRATE AFTER A PLATING PROCESS | LAM RESEARCH (US) | 2010-03-11 | — | — | WO | claimed |
| US-20100062164-A1 | Methods and Solutions for Preventing the Formation of Metal Particulate Defect Matter Upon a Substrate After a Plating Process | LAM RESEARCH (US) | 2010-03-11 | — | — | US | claimed |
| CN-1013859-B | IMPROVEMENTS FOR SYNTHESIS OF CITRIC ACID TRIPHENYLAMINE OXIDE | INST NO 4 ANTICHEMICAL I PLA (CN) | 1991-09-11 | — | — | CN | claimed |
| CN-86107840-A | The improvement of synthesis of citric acid triphenylamine oxide | — | 1988-06-01 | — | — | CN | claimed |
| US-12629387-B2 | Composition of antiviral agent for use in prophylactic or post-exposure treatment of infectious or respiratory diseases | INSPIRMED CORP. (TW) | 2026-05-19 | — | — | US | disclosed |
| US-20230181615-A1 | COMPOSITION OF ANTIVIRAL AGENT FOR USE IN PROPHYLACTIC OR POST-EXPOSURE TREATMENT OF INFECTIOUS OR RESPIRATORY DISEASES | INSPIRMED CORP (TW) | 2023-06-15 | — | — | US | disclosed |
| EP-4125810-A1 | COMPOSITION OF ANTIVIRAL AGENT FOR USE IN PROPHYLACTIC OR POST-EXPOSURE TREATMENT OF INFECTIOUS OR RESPIRATORY DISEASES | InspirMed Corp. (TW) | 2023-02-08 | — | — | EP | disclosed |
| CN-115315252-A | Antiviral composition for preventing or treating infection or respiratory disease after exposure | 盈擘医药股份有限公司 | 2022-11-08 | — | — | CN | disclosed |
| US-20220211623-A1 | INHALABLE SUSTAINED RELEASE COMPOSITION OF BRONCHODILATOR FOR USE IN TREATING PULMONARY DISEASE | INSPIRMED CORP. (TW) | 2022-07-07 | — | — | US | disclosed |
| WO-1991016878-A1 | CLEAN CONDITIONING COMPOSITIONS FOR HAIR | THE PROCTER & GAMBLE COMPANY (US) | 1991-11-14 | — | — | WO | disclosed |
| CN-1056051-A | The vehicle system that is used for cosmetic composition | PROCTER & GAMBLE (US) | 1991-11-13 | — | — | CN | disclosed |
| WO-1991015186-A1 | HAIR STYLING CONDITIONERS | THE PROCTER & GAMBLE COMPANY (US) | 1991-10-17 | — | — | WO | disclosed |
| CN-1013859-B | IMPROVEMENTS FOR SYNTHESIS OF CITRIC ACID TRIPHENYLAMINE OXIDE | INST NO 4 ANTICHEMICAL I PLA (CN) | 1991-09-11 | — | — | CN | disclosed |
| CN-86107840-A | The improvement of synthesis of citric acid triphenylamine oxide | — | 1988-06-01 | — | — | CN | disclosed |
| EP-0217635-A2 | Hair treatment | THE PROCTER & GAMBLE COMPANY (US) | 1987-04-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12629387-B2 | Composition of antiviral agent for use in prophylactic or post-exposure treatment of infectious or respiratory diseases | IFNAR1, NPC1, SGMS1 | MEN1 3475/4885ALDH1A1 4342/4885HMGCR 66/4885 |
| US-20230181615-A1 | COMPOSITION OF ANTIVIRAL AGENT FOR USE IN PROPHYLACTIC OR POST-EXPOSURE TREATMENT OF INFECTIOUS OR RESPIRATORY DISEASES | LIPA, MAVS, ISG15 | MEN1 2858/4885ALDH1A1 3863/4885HMGCR 1863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.